# Immuneering

Source: https://onco.cc/companies/immuneering/  
OnCo record `immuneering` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immuneering is a United States-based biotechnology company running 2 late-stage cancer trials of Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer.

## Summary

Immuneering, based in Cambridge, the United States, is a biotechnology company. Immuneering is a biotechnology company developing oncology treatments based on 'Deep Cyclic Inhibitors', a pulsed dosing approach to MAPK-pathway inhibition intended to reduce cancer resistance while improving tolerability. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer. The largest, NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), plans to enrol 510 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Immuneering Corporation
- Tags: ctgov-sponsor
- HQ: Cambridge
- Type: biotech
- Website: https://www.immuneering.com

## Sources

- Official website: https://www.immuneering.com
- ClinicalTrials.gov: trials led by Immuneering: https://clinicaltrials.gov/search?lead=Immuneering%20Corporation
- Pipeline page: https://www.immuneering.com/pipeline

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Atebimetinib](https://onco.cc/drugs/atebimetinib/)
- trials: [A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05585320/), [Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07562152/)

---
JSON: https://onco.cc/api/v1/entities/immuneering.json